A539index on 12 -24 and 96 -104 weeks of therapy. The costs of drug treatment from Russian healthcare system perspective were calculated for 2 years. Drug prices were derived from the list of registered maximal manufacture's prices for vital and essential drugs; expected price of secukinumab was submitted by its manufacturer. Oneway sensitivity analysis was performed. Results: Secukinumab has the lowest ICER among all biologic drugs indicated for AS treatment in Russia -€ 26,637 per patient, who has achieved ASAS20 response at 2 years. Secukinumab is also cheaper than all other biologic agents: its cost for 2 years is € 15,343, while other drugs require from € 15,926 to € 46,995 over the same period. The price of secukinumab should increase at least up to 3,6% from presently expected in order it to lose its advantages over other biologics. ConClusions: Secukinumab will provide a new cost-effective option for AS treatment in Russian Federation if the expected price is not changed.

No abstract

No abstract

No abstract